The application of structure-based assessment to support safety and chemistry diligence to manage genotoxic impurities in active pharmaceutical ingredients during drug development-Reference-Cited by-同舟云学术

The application of structure-based assessment to support safety and chemistry diligence to manage genotoxic impurities in active pharmaceutical ingredients during drug development

Published:2006-04 Issue:3 Volume:44 Page:282-293
ISSN:0273-2300
Container-title:Regulatory Toxicology and Pharmacology
language:en
Short-container-title:Regulatory Toxicology and Pharmacology

Author:

Dobo Krista L.,Greene Nigel,Cyr Michelle O.,Caron Stéphane,Ku Warren W.

Publisher

Elsevier BV

Subject

Toxicology,General Medicine

Reference41 articles.

1. Anonymous, 2000. Alkyl mesilate (methanesulfonate) impurities in mesilate salts. Pharmeuropa 12, 27.

2. Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the US NTP;Ashby;Mutat. Res.,1991

3. Prediction of rodent carcinogenicity for 44 chemicals: results;Ashby;Mutat. Res.,1994

4. The influence of chemical structure on the extent and sites of carcinogenesis of 522 rodent carcinogens and 55 different human carcinogen exposures;Ashby;Mutat. Res.,1993

5. Classification according to chemical structure mutagenicity to Salmonella and level of carcinogenicity by the U.S. National Toxicology Program;Ashby;Mutat. Res.,1989

Cited by 102 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sensory detection of selective substituted acyl chloride and nitrobenzene sulfonyl chloride by interaction with 1-amino-4-hydroxy-9,10-anthraquinone using spectrophotometry and cyclic voltammetry;Chemical Papers;2024-06-22

2. Sensory detection of selective substituted acyl chloride and nitrobenzene-sulfonyl chloride by interaction with 1-amino-4-hydroxy-9,10-anthraquinone using spectrophotometry and cyclic voltammetry;Chemical Papers;2024-06-11

3. Genetic Toxicology Testing;A Comprehensive Guide to Toxicology in Nonclinical Drug Development;2024

4. Control Strategies for Mutagenic Impurities;Mutagenic Impurities;2021-12-08

5. Addressing the Complex Problem of Degradation‐Derived Mutagenic Impurities in Drug Substances and Products;Mutagenic Impurities;2021-12-08